Avalyn Pharma appoints former FDA director Robert Meyer to board

Avalyn Pharma Inc.

Appointed Robert Meyer, M.D. as Class II director effective Sept 15, 2026; term expires at 2028 annual meeting.
Meyer is independent under Nasdaq rules; ex-FDA drug evaluation director and Merck VP for global regulatory strategy.
Eligible for $40,000 annual retainer; initial option for 31,182 shares vesting over 3 years plus annual 15,591-share grants.
No arrangements or transactions requiring disclosure; signed standard indemnification agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.